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The Conference on Retroviruses and
Opportunistic Infections (CROI) is the premier
domestic venue for the dissemination of data
related to the clinical management of HIV infec-
tion.  Smaller and more focused than most other
meetings covering the care for persons living with
HIV, CROI is data dense and always guaranteed
to yield findings that influence how HIV infection
is treated.
This February the conference was held in down-
town Los Angeles, a few short miles from where
the Academy Awards ceremony takes place,
which was occurring as CROI opened.  However,
it was all business and little glamour in the con-
ference center as attendees rushed from session
to session, crisscrossing as they pursued their
disparate interests. 
IDCR editors and Board members were among
the throngs jockeying for aisle seats with excel-
lent views of the slide presentations.  No papers
directly related to the care of the HIV-infected
inmate, but the major findings presented are rel-
evant for anyone managing HIV infection.  Below,
our team of experts provides summaries of the
data they felt would be of greatest importance to
you, their correctional colleagues.
New antiretroviral agents
As the HIV epidemic matures and the prevalence
of the infection rises, an increasing number of
HIV-infected patients will receive antiretroviral
HIV therapy. Unfortunately, many will harbor or
develop a virus with antiretroviral drug resistance.
HIV-infected men and women cycling in and out
of prisons and jails may be particularly vulnerable
to the development of drug resistant HIV as they
may initiate, interrupt and re-initiate care during
and between incarcerations. Infected inmates
may also face a number of challenges to adher-
ence with their HIV therapies including mental ill-
ness and substance abuse.  
Results from a number of important clinical trials
of new antiretroviral drugs were presented at
CROI 2007 and offer hope for patients infected
with multidrug resistant HIV.  We report on two
new antiretroviral agents that are relatively
advanced in their clinical development, are cur-
rently available via expanded access programs,
and may be of immediate clinical interest. These
drugs represent two novel antiretroviral classes
and have the potential to positively impact treat-
ment outcomes as well as change the prevailing
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IDCR and AAHIVM have united to improve
the quality of health care delivery in the
nation's correctional facilities by leveraging
the knowledge, experience and resources of
two diverse and accomplished groups of HIV
and correctional health care experts. 
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Dear Correctional Colleagues,
One of the most exciting but challenging aspects of providing HIV care is the dizzying speed with
which new developments in the field are reported and then incorporated into clinical practice.
New drugs are developed, studied and fast-tracked for approval; meanwhile, clinical trial results
are made public and before you can say 'press release' are influencing treatment decisions in the
clinic.   
To keep up, clinicians caring for HIV-infected individuals must look to a number of sources of infor-
mation.  One such resource you are holding in your hands (to those of you online, my apologies).
In addition, there are an array of conferences showcasing the latest data in advance of publica-
tion.  
You would not know it from its longwinded and anachronistic name but the Conference on
Retroviruses and Opportunistic Infections (CROI) is the top U.S. HIV conference in this country.
Held annually, CROI is jam-packed with information on treatment, complications and prevention.
It is a tough meeting to cover.  There are so many important presentations that it is difficult to 
distill the most significant into a single summary.  But, in this issue we do just that.  Our team of
correctional experts was in Los Angeles and together have written a concise review of the meet-
ing mindful of the types of information that would interest a readership of correctional health care
providers.  We supplement our conference coverage with actual clinical case studies that incor-
porate data presented at CROI.  For more information about the conference and the data that
were presented there, check out our Resource section for links to the conference and other sites
containing conference summaries and analyses.  
An old AIDS activist battle cry was, "Knowledge = Power."  Many of those activists may be gone
but with more to know, their words were never truer.  We at IDCR are proud to be able to provide
these kinds of reviews to our colleagues working along side us in our prisons and jails.  We hope
you value the newsletter as an objective source of information from clinicians who 'walk the walk'
of correctional health care.  If you do, please let our sponsors' representatives know that their
suport is a worthwhile investment.  Of course, also feel free to share your appreciation of IDCR
with representatives of those who, as of yet, have not chosen to support our modest 
publication. It can't hurt.  
Sincerely, 
David A. Wohl, MD
Associate Professor of Medicine
Division of Infectious Diseases
AIDS Clinical Research Unit 
The University of North Carolina - Chapel Hill
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treatment paradigm of combining two nucle-
osides with a protease inhibitor or a non
nucleoside reverse transcriptor inhibitor as
the cornerstone of highly active antiretroviral
therapy (HAART).
Maraviroc
To gain entry into CD4 cells, HIV must inter-
act with not only the CD4 receptor but with
other cellular receptors including those for
chemokines CCR5 and CXCR4.  Maraviroc
(MVC) is an entry inhibitor that is a CCR5
(R5) antagonist with in vitro activity against
virus that is tropic for cells that express the
R5 receptor but not cells that use CXCR4
(X4) receptors or that use both types of
receptors (i.e. dual tropic HIV-1). Interim 24-
week analyses of two parallel ongoing phase
IIb/III double-blind, placebo-controlled stud-
ies of MVC in antiretroviral treatment-experi-
enced, HIV-infected adults, MOTIVATE
(Maraviroc Plus Optimized Background
Therapy in Viremic, ART-Experienced
Patients) 1 and 2, were presented.1,2 These
studies were identical in design and were
conducted in the U.S. and abroad.  Eligible
participants were triple antiretroviral class-
experienced with viremia of > 5000
copies/ml, had only R5 tropic virus on base-
line tropism screening, and were randomized
1:2:2 to receive placebo, twice daily MVC
300 mg or once daily MVC 300 mg. An opti-
mized background therapy (OBT) was
selected by the treating physicians to accom-
pany the study treatment. The dose of MVC
was reduced to 150 mg if the OBT contained
protease inhibitors (except tipranavir) or
delavirdine. Participants were further strati-
fied by enfurvitide (T-20) use or by HIV-1
RNA value above or below 100,000
copies/ml (see Table 1).  
At 24 weeks, MVC plus OBT provided supe-
rior virologic and immunologic outcomes
compared to placebo plus OBT. Overall, sim-
ilar results were noted for MVC once daily
and twice daily dosing regimens.  However, a
larger proportion of patients who were found
on antiretroviral resistance testing to have no
active drug in OBT achieved HIV-1 RNA
below 50 copies/ml in the two MVC BID arms
compared to MVC QD or placebo arms in
combined analysis (29% vs. 18% vs. 3%
respectively in an analysis combining the
results of the two trials). 
No differences in the reduction in HIV-1 RNA
were noted when results were stratified by
receipt of enfuvirtide or by baseline HIV-1
RNA values.  Adverse events were similar in
all arms. Specifically, no increased risk of
lymphoma or other malignancies was
observed in the MVC arms compared to the
placebo arm.  In the subset of patients that
failed treatment, patients receiving MVC
were much more likely to have had shifts to
X4 or dual tropic virus than those receiving
placebo (see Table 1). 
MCV is scheduled in April for review by the
FDA for accelerated approval.  It represents
a welcomed addition to our antiretroviral
armamentarium but its optimal role in anti-
retroviral therapy remains to be defined.
Chemokine receptor inhibitors are the first
antiretroviral drugs that target host proteins
rather than viral targets. While the apparent
absence of any significant sequelae among
individuals with congenital deficits in
chemokine receptors (e.g., CCR5-^32
homozygotes) provides some reassurance
that the therapeutic use of chemokine recep-
tor inhibits will be similarly benign, the long-
term safety of CCR5 inhibition is yet to be
proven. Recent reports that homozygous
CCR ^32 is a strong host genetic risk factor
for symptomatic laboratory-confirmed West
Nile Virus infection further fuels safety con-
cerns.3 Similarly, initial concerns regarding
the emergence of X4 virus during treatment
with an R5 antagonist remain. Additionally,
the clinical use of MVC, in particular in treat-
ment-experienced patients, appears to
require pretreatment screening with a tro-
pism assay because the drug will not be
effective in those infected with an x4 or dual
tropic virus. The expense of such assays
may strain already stretched financial
resources.  Finally, resistance to R5 antago-
nists is incompletely understood.
Raltegravir
Raltegravir, previously known as MK-0518, is
an integrase inhibitor that has previously
been shown to confer significant virologic
benefit to antiretroviral-naïve HIV-infected
patients, as well as heavily treatment-experi-
enced patients with HIV resistant to agents in
each of the three original antiretroviral drug
classes. The integrase enzyme is responsi-
ble for incorporating viral DNA into the host
genome where, once integrated, it encodes
for the production of viral proteins.  As such it
has been an attractive but elusive antiretrovi-
ral target.  Sixteen-week data from two iden-
tical, parallel, ongoing, phase III double-
blind, placebo-controlled studies, designated
BENCHMRK-1 and -2, were presented at
CROI 2007.4,5 Eligible participants were
those failing antiretroviral therapy with triple
antiretroviral class resistance and were ran-
domized 2:1 to raltegravir 400 mg twice daily
or placebo. OBT was selected by the treating
physicians. Selected drugs that were investi-
gational at the time the study was conducted
(e.g. darunavir) were permitted to be part of
OBT (see Table 2).  
Raltegravir demonstrated superior virologic
and immunologic efficacy at 16 weeks over
placebo. Superior efficacy of the raltegravir
arms was maintained regardless of baseline
CD4 count, HIV-1 RNA values as well as pre-
dicted resistance to agents in the OBT by
resistance testing. Adverse events were sim-
ilar between groups (see Table 2). 
Raltegravir has shown impressive efficacy in
both antiretroviral naïve and treatment-expe-
rienced patients. While its approval by the
FDA is eagerly anticipated, its optimal role in
the sequence of antiretroviral therapy
remains to be well defined.
Current antiretrovirals
Once daily versus twice a day lopinavir/riton-
avir and the role of directly observed therapy
(DOT)
Once daily antiretroviral regimens have
become de rigueur for reasons that are obvi-
ous to anyone who must take medications
chronically. It is hoped that simplification of
HIV therapy will improve adherence, howev-
er few studies have examined the relative
efficacy of once daily and twice daily admin-
istration of the same antiretroviral agents.
Once daily HIV therapy regimens also make
direct observation of dosing more feasible.
Certainly, no one has more experience
administering antiretrovirals via directly
observed therapy (DOT) than correctional
facilities. Yet, again, there are limited data
available regarding the role for DOT in HIV
care.  
AIDS Clinical Trials Group (ACTG) study
A5073 aimed to compare the safety and viro-
logic efficacy of lopinavir/ritonavir dosed at
800/200 mg once a day (n=159) versus
400/100 mg twice a day (n=161) in treatment
naïve patients.6 The drug was combined with
emtricitabine (FTC) plus either tenofovir
(used in ~ 40% of subjects) or stavudine-XR.
In addition, a third arm of the study adminis-
tered the once daily regimen under DOT for
24 weeks (n=82).  In this study DOT consist-
ed on the observation of ingestion of the
lopinavir/ritonavir five days of the week by a
health professional (e.g. doctor, nurse, phar-
macist).
By 48 weeks after study entry, there was no
overall difference in time to virologic failure
between the self-administered once daily
versus twice daily study arms with about
30% of patients in each experiencing failure
by this time point.  However, when stratifying
response by baseline viral load, among
those with a HIV-1 RNA level > 100,000
copies/mL, virologic failure was more com-
mon with self-administered once daily
lopinavir/ritonavir compared to self-adminis-
tered twice a day lopinavir/ritonavir.
Seventy-four percent of those assigned to
DOT of once daily lopinavir/ritonavir complet-
ed the 24 week DOT program. There was
86% adherence with the DOT visits among
these participants.  There was a trend favor-
ing DOT at the end of the 24 weeks in com-
paring the self administered once daily
lopinavir/ritonavir arm to the DOT once daily
lopinavir/ritonavir arm, but this did not
achieve statistical significance.  By week 48
(24 weeks after DOT ceased) there was no
difference in the probability of virologic failure
between the DOT and self-administered
once daily therapy arms.  Over the 48 weeks
of study, there was a trend toward fewer new
AIDS diagnoses and deaths among those
getting their treatment via DOT, but there
were too few events to make firm conclu-
sions regarding this finding.  
This trial found that once daily lopinavir/riton-
avir can be most safely administered to
patients with a pre-therapy viral load of less
than 100,000 copies/mL. The unexpected
finding of increased risk of virologic failure
among those with higher viral loads assigned
to once a day lopinavir/ritonavir is concerning
and requires further study.  Modified DOT
(i.e. observation of some but not all doses)
was not found to produce remarkable advan-
tages over self-administered therapy in this
community-based study, although there were
intriguing trends in better virologic responses
and clinical outcomes among those getting
their HAART under study-defined DOT.
These trends will likely spur increased efforts
to study community-based DOT for HIV treat-
ment.
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Early failure of tenofovir, lamivudine (3TC)
and nevirapine
HIV health care providers frequently must be
creative in crafting antiretroviral regimens.
While published guidelines assist clinicians
in choosing appropriate therapy for patients
starting HIV treatment, patients may have
adverse reactions to recommended agents
or other contraindications that require con-
sideration of alternative combinations.
Investigators in France conducted a trial
comparing tenofovir, lamivudine (3TC) and
nevirapine versus zidovudine (ZDV), 3TC
and nevirapine among treatment naïve
patients.7 The study was designed to enroll
250 people, but was halted after 71 were ran-
domized as there was an excess of virologic
failures in the tenofovir, 3TC and nevirapine
arm.  Nine of 36 participants assigned to that
arm, compared to only one of 35 receiving
ZDV, 3TC and nevirapine, failed.  Only one of
the ten patients who failed therapy had base-
line resistance.  Nevirapine levels were mea-
sured and found to be adequate in all failure
patients.  Mutations conferring resistance to
nevirapine were the most commonly detect-
ed mutations observed followed by the K65R
mutation, associated with tenofovir resis-
tance and the M184V 3TC mutation.  
This study serves as a cautionary tale
regarding the use of untested antiretroviral
regimens, particularly in treatment naïve
patients who are able to take more standard
combinations.  The reason for the early fail-
ure of tenofovir, 3TC and nevirapine remains
unclear and is unexpected given the proven
potency of tenofovir, 3TC and efavirenz.
Further examination of these data and this
regimen are needed.  Until then, avoiding
this particular regimen seems prudent.  
Safely dosing H2 blockers with
atazanavir/ritonavir
Atazanavir is a protease inhibitor that
requires gastric acid to be adequately
absorbed. Therefore, co-administration of
proton pump inhibitors and atazanavir is con-
traindicated. Previous data demonstrate that
H2 blockers, specifically famotidine, can be
used during atazanavir therapy.  According to
the package insert, in treatment-naïve
patients atazanavir at a dose of 300 mg with
ritonavir 100 mg once daily can be taken with
food, without the need for separation of the
dose from the H2-receptor antagonist. In
treatment-experienced patients it is recom-
mended that atazanavir/ritonavir 300/100 mg
once daily be taken with food at least 2 hours
before and at least 10 hours after the H2-
receptor antagonist.   
In a study of HIV-uninfected volunteers,
atazanavir/ritonavir in standard doses along
with tenofovir was administered with famoti-
dine either simultaneously or temporally sep-
arate (10 h before and 4 h after).8 Tenofovir
is commonly prescribed with ritonavir boost-
ed atazanavir even though this nucleotide
analogue reduces atazanavir levels - an
effect that is largely overcome with ritonavir
boosting.  In this study, atazanavir levels
were adequate when famotidine 20 mg BID
Continued on page 5
Table 1.  Results of MOTIVATE 1 and 2 Trials of Maraviroc for Salvage HIV Therapy (Results in parenthesis are
for MOTIVATE 2).
N
Median baseline CD4 count
(cells/mm3) 
Mean baseline HIV-1 RNA log10
copies/ml
Proportion of patients with enfuvirtide
in OBT
Proportion of patients with < 2 active
drugs predicted by resistance testing
in OBT 
Mean change in HIV-1 RNA (log10
copies/ml )from baseline to 24 weeks 
Mean change in CD4 count
(cells/mm3) from baseline to 24
weeks
Proportion  of patients with HIV-1
RNA <400 copies/ml
Proportion of patients with HIV-1 RNA
<50 copies/ml
118 (91)
163 (174)
4.84 (4.89)
42% (45%)
66.1% (66.0%)
-1.03 (-0.93)
+52 (+64)
31.4% (23.1%)
24.6% (20.9%)
232 (182)
168 (174)
4.85 (4.84)
43% (37%)
68.5% (62.6%)
-1.82 (-1.95)
+107 (+112)
54.7% (55.5%)
42.2% (45.6%)
235 (191)
150 (182)
4.86 (4.87)
46% (39%)
75.7% (62.3%)
-1.95 (-1.97)
+111 (+102)
60.4% (61.3)
48.5% (40.8%)
Placebo MVC QD MVC BID
Table 2.  Results of BENCHMRK 1 and 2 Trials of Raltegravir for Salvage HIV Therapy (Results in parenthesis are
for BENCHMRK 2)
N
Mean baseline CD4 count (cells/mm3)
Mean baseline HIV-1 RNA log10 copies/ml
Mean change in CD4 count (cells/mm3) from baseline to 16
weeks
Proportion  of patients with HIV-1 RNA <400 copies/ml
Proportion of patients with HIV-1 RNA <50 copies/ml
118 (119)
153 (163)
4.5 (4.7)
+31 (+40)
41% (43%)
33% (36%)
232 (230)
156 (146)
4.6 (4.7)
+83 (+86)
77% (77%)
61% (62%)
Placebo Raltegravir
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was given with or separate from ATV+RTV
dose.  Likewise, atazanavir levels were ade-
quate when famotidine at a dose of 40 mg
daily was given separate from the protease
inhibitors.  However, atazanavir levels were
significantly reduced when famotidine at 40
mg BID was given, even when administered
separately from the protease inhibitors.
Therefore, twice daily dosing of this H2
blocker at the higher dose should not be
administered to patients on atazanavir and
should be used cautiously with this boosted
protease inhibitor even at lower doses.
Metabolic complications
There were several important presentations
regarding metabolic complications of HIV
and its therapies. Most notable were the
metabolic results of ACTG trial A5142, a
large study comparing a) efavirenz plus two
nucleoside analogues, b) lopinavir/ritonavir
plus two nucleoside analogues and c)
efavirenz and lopinavir/ritonavir without
nucleosides.9 The virologic and immunolog-
ic results of the trial were presented at the
International AIDS Conference last summer
(see IDCR September 2006).  
At CROI 2007, the relative effects of each of
the three study arms on limb fat and lipids
were presented and were surprising to many.
Foremost, over 96 weeks, those patients
assigned to efavirenz plus two nucleosides
experienced an initial increase in total limb
fat of approximately 8% by 48 weeks but this
declined precipitously to just a 1.4% gain
over baseline at 96 weeks.  This is in stark
contrast to those randomized to
lopinavir/ritonavir and two nucleosides who
experienced an increase in limb fat of almost
10% by week 48, which persisted at 96
weeks.  The nucleoside-sparing regimen pro-
duced progressive limb fat gains during the
study reaching 18% at week 96.  
Importantly, the nucleoside agents used in
the two arms containing this class of anti-
retrovirals was balanced between the arms
with about 40% using ZDV, 30% using teno-
fovir and the remainder choosing stavudine-
XR.  Even among those taking tenofovir, a
drug not thought to contribute to fat wasting,
there was more lipoatrophy (>20% limb fat
loss from baseline) among those assigned to
take efavirenz (12%) than lopinavir/ritonavir
(6%).   The rise and fall of limb fat seen in the
efavirenz plus two nucleoside group was
similar to the changes seen in the
ZDV+3TC+efavirenz arm of another study
presented at CROI 2007 - a trial of this com-
bination versus lopinavir/ritonavir monother-
apy after withdrawal of ZDV+3TC once viral
suppression was achieved.10 In that study,
as in A5142, the ZDV+3TC+efavirenz arm
experienced an early increase in limb fat fol-
lowed by a progressive decline over time.  In
this case, there was a net loss of fat com-
pared to baseline in this group. 
Defying predictions, increases in total cho-
lesterol during A5142 were no different in the
lopinavir/ritonavir and the efavirenz arms, ris-
ing approximately 30 mg/dL in each group.
In contrast, the nucleoside sparing arm had a
statistically significant greater increase of
57mg/dL at week 96.  Triglycerides rose
higher after the initiation of therapy in the
lopinavir/ritonavir plus two nucleoside arm
(46 mg/dL) compared to the efavirenz arm
(19 mg/dL). And, again, the efavirenz plus
lopinavir/ritonavir group saw the greatest
increase (62mg/dL).  
This important trial reveals that combinations
of antiretrovirals can act together to produce
peripheral fat wasting. In addition, the per-
ception that metabolic toxicities belong sole-
ly within the province of protease inhibitors is
demonstrated to be incorrect. Indeed, in this
trial there were no differences seen between
the study arms in changes of trunk fat - an
adverse effect that is typically ascribed to
protease inhibitors.
HCV therapy
Lessons from clinical trials of HIV/HCV co-
infected patients
In correctional settings, we have traditionally
thought of HCV as being primarily a blood-
borne infection.  Data from CROI, however,
challenge this notion and may have impor-
tant implications for more routine testing for
HCV in populations not previously thought to
be at highest risk.  In one study of 7223 men
who have sex with men (MSM) in the U.K.,
increased risk for HCV infection included
unprotected sex, multiple sexual partners
and the presence of other sexually transmit-
ted infections, such as gonorrhea and
syphilis. HCV transmission among this
cohort appeared to increase among HIV-
infected individuals, perhaps due to the high-
er levels of HCV viremia and impaired
immunological responses.11 Correctional
inmates before, during or after release
engage in many of the risks identified in this
study and merit increased screening and risk
behavior counseling.  
In a plenary session by David Thomas, MD,
from Johns Hopkins University, the pros and
cons of liver biopsy in HCV/HIV co-infected
patients were thoroughly discussed.12 Unlike
the case for HIV where surrogate markers
such as viral load and CD4 cell count are the
best predictors of disease progression, the
extent of hepatic fibrosis is the best prognos-
tic factor for progression of liver disease  in
HCV-infected patients. Liver biopsy has been
the primary tool for assessing hepatic fibro-
sis, yet is subject to several important limita-
tions including: 1) its invasive nature with
potential for significant complications; 2) the
possibility of sampling error due to a relative-
ly small biopsy size (1/50,000th of the
liver)13, the fragmentation of examined tis-
sue, and/or the inherent heterogeneity of
hepatic fibrosis 14; 3) low acceptance by
many patients; 4) cost considerations; and 5)
lack of availability.  While liver biopsy has the
advantage of providing additional information
on other relevant histologic findings, such as
necroinflammation and steatosis, some
argue that its use in patients with HIV co-
infection has less merit given the accelerated
rate of progression among HIV-infected
patients and their high rates of liver disease-
related morbidity and mortality.15,16
Nonetheless, development of noninvasive
tools for staging hepatic fibrosis has been
urgently needed.
Assessing liver fibrosis using non-invasive
procedures has been divided into two distinct
categories:  1) imaging techniques, such as
elastometry (e.g., FibroScan), and serum
biochemical marker tests (e.g., Fibrotest,
APRI, SHASTA, FIB-4, Forns, serum
hyaluronic acid).17 These tools are generally
accurate in discriminating between a lack of
fibrosis and advanced fibrosis, but they are
less precise at distinguishing between inter-
mediate fibrosis stages. The predictive value
of these tests is particularly good for
advanced hepatic fibrosis and cirrhosis. Liver
fibrosis staging using elastometry seems to
be particularly reliable. Assessed within 10
minutes, it is relatively low cost, can be
repeated frequently without risk to the
patient. It also has a positive predictive value
greater than 90% for advanced fibrosis. 
Despite these advances, waiting until a
patient has advanced fibrosis for treatment is
less than optimal in HCV/HIV co-infected
patients.  Instead, Thomas recommends that
when chronic HCV infection is clear by the
presence of HCV viremia alone, in the
absence of other clinical indicators that
would preclude treatment (e.g., Childs Pugh
B or C cirrhosis, suggestion of autoimmune
hepatitis, advanced and uncontrolled HIV
infection or presence of opportunistic infec-
tion) is sufficient to warrant treatment.12 The
relatively high response to pegylated interfer-
on plus weight-based ribavirin, the faster pro-
gression of HCV-related liver disease in the
HCV/HIV co-infected population, and the
opportunity for assessing the HCV response
at earlier time points to identify who will and
will not respond to therapy all favor initiating
anti-HCV therapy without the need for a liver
biopsy in most cases.
In the following plenary session, Raymond
Chung, MD, from Harvard University,
reviewed that current HCV treatment in HIV
co-infected patients.18 In addition to review-
ing the three large prospective trials treating
HCV among HCV/HIV co-infected patients,
where sub-therapeutic ribavirin dosing was
used (APRICOT19, ACTG 5071 20, and RIB-
AVIC21), updated data from the PRESCO
trial using weight-based ribavirin doses of
1000 to 1200 mg per day presented at CROI
were also reviewed.22
The PRESCO trial demonstrated increased
sustained virologic response rates (SVR,
undetectable HCV viral load six months after
treatment completion) (49.6%) compared to
other studies. The PRESCO trial also con-
firmed low rates of premature discontinuation
(8.2%) - similar to trials of weight-based rib-
avirin and pegylated interferon in HCV mono-
infected patients. The PRESCO trial
answered some additional questions.  First,
the SVR among genotype 1 was 35.6% and
72.4% in genotypes 2 and 3.  The study was
also designed to address the issue of treat-
ment duration (short vs. extended tended).
Patients with genotypes 2 or 3 were random-
ized to receive 24 weeks (short) versus 48
weeks (extended) of treatment and patients
with genotypes 1 or 4 received 48 weeks
(short) versus 72 weeks (extended) of treat-
ment.  SVR rates were higher among
patients assigned to received extended ver-
sus standard durations of therapy.  For geno-
types 2 or 3, SVR was 82% with 48 weeks
versus 67% with 24 weeks.  For genotypes 1
or 4, 53% had SVR with 72 weeks versus
31% with 48 weeks.  Extended treatment
duration did not, however, decrease the like-
lihood of relapse in patients with genotype 1
(33%) or genotypes 2 or 3 (17%), but did
reduce relapse rates from 21% to 0% in
Continued on page 6
April 2007      Vol. 9, Issue 15 visit IDCR online at www.IDCRonline.org
6COVERAGE OF THE 14TH CONFERENCE...
(continued from page 5)
patients with genotype 4. Extended treat-
ment was associated with increased toxicity
and drop-out.23
Further data from CROI suggested that
improved outcomes can be achieved if HIV
infection is optimally managed (e.g., exclud-
ing individuals receiving zidovudine or
didanosine or patients with low CD4 cell
counts and uncontrolled HIV RNA levels).24
In addition to this data on extended duration
of treatment for HCV/HIV co-infection, a
number of additional clinical pearls were
gleaned from other presentations that should
assist with optimizing HCV treatment.  A sub-
study of the RIBAVIC trial demonstrated
reduced SVR among patients concomitantly
receiving abacavir and ribavirin, suggesting a
potential drug interaction between the two
guanosine analogues.25 Though not clinical-
ly available to clinicians now, the use of tran-
scription-mediated amplification (TMA), a
very sensitive tool that has a lower limit of
HCV RNA detection of 5 IU/mL, for detecting
serum HCV RNA at the end of a course of
HCV treatment has positive and negative
predictive values exceeding 80% for
relapse.26 Tools similar to this one, rather
than extended treatment courses, will help
individualize treatment duration.  
More data supportive for dispensing with
transaminase elevations as a guide for treat-
ment evaluation were presented. Matched
HCV/HIV co-infected patients with persis-
tently normal versus elevated transaminase
levels were compared.  Among patients with
advanced liver fibrosis (Metavir scores of F3
or F4) nearly 15% of co-infected patients had
persistently normal transaminases; this find-
ing was more frequent among women and
those with genotype.4 Thus, co-infected
patients with normal liver enzyme levels
should not be excluded from anti-HCV thera-
py, as liver disease progression may occur in
a significant proportion of these patients in a
silent manner.
Who gets treated and who does not
HCV therapy is becoming increasingly avail-
able in correctional facilities.  A study from
Johns Hopkins University looked at eligibility
of HIV/HCV co-infected and HCV mono-
infected injection drug users (IDUs) for HCV
therapy.27 Patients studied included 180
HCV mono-infected individuals participating
in a community-based Hopkins-run addiction
treatment program and 183 HIV/HCV co-
infected patients of the hospital's HIV clinic.
All were offered free HCV therapy (see Table
3).
Eleven percent of the co-infected patients
had a negative HCV RNA as did 22% of the
mono-infected. More of the HIV-infected
patients (40%) were deemed ineligible for
HCV treatment due to having a life expectan-
cy less than two years, active depression
with suicidal ideation, allergic reaction to
interferon or ribavirin, severe hepatologic
abnormalities, renal insufficiency, pregnancy,
or unwillingness to use birth control than the
HIV-uninfected (26%).  However, a similar
proportion of patients (66-67%) did not start
HCV therapy (see Table 3).  
Therefore, HIV co-infected patients were less
likely to be eligible for HCV therapy - largely
as a consequence of poor life expectancy
and anemia - but the eligible mono-infected
patients were less likely to actually start HCV
treatment.  In both groups, the vast majority
of HCV eligible patients never initiated HCV
treatment. The investigators also reported
that most patients (79% in the mono-infected
group and 67% among the co-infected) had
no or minimal fibrosis seen on liver biopsy -
perhaps suggesting that disease staging had
an influence on the uptake of HCV treatment
(see Table 3).
Conclusions
As usual, there were a number of presenta-
tions at CROI of great interest to the HIV clin-
ician.  The results of phase III trials of two
new HIV therapies belonging to novel class-
es of antiretrovirals produced palpable
excitement at the conference as clinicians
recognized that a critical mass of new thera-
pies for the patient with multi-drug resistant
virus was at hand.  However, for correctional
clinicians unresolved issues related to the
need to assess viral tropism prior to therapy
initiation may temper enthusiasm for MVC.
These assays are likely to carry a significant
price tag and it may take weeks for a result to
return.   During that time as many as 8% of
patients may experience a shift in viral tro-
pism from R5 to dual/mixed virus.  It is only a
matter of time (measured in months) before
the first correctional physicians will be pre-
scribing these new agents and these issues
will need to be addressed by the manufac-
turer of this important new agent. 
Other clinical trial data refined our under-
standing of current management of HIV and
HCV infections - helping us to better tailor
therapy to the individual patient.  Thus, while
no presentation focused specifically on the
HIV epidemic in corrections, there was plen-
ty here for correctional clinicians to learn and
use.
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Disclosures: Nothing to Disclose
Case 1: D.T. is a 43 year-old male inmate
diagnosed with HIV infection in 1994 who has
a history of AIDS (by CD4 cell count), distal
peripheral neuropathy, hypertriglyceridemia
and major depression.  He presents for a rou-
tine infectious diseases clinic appointment
two months after being incarcerated with a
complaint of extreme fatigue.  He recently
had routine laboratories performed and these
were normal except for a platelet count of 118
thousand. His hepatitis B surface antibody is
positive but his hepatitis C antibody is nega-
tive. He is serving a four-year prison sen-
tence.
He has a history of less than perfect adher-
ence in years past, partially due to depres-
sion and lack of ability to tolerate medica-
tions.  His nadir (lowest ever) CD4 cell count
was 60/mm3 in August of 2002.  At his last
visit six weeks prior his HIV RNA PCR (viral
load) was 17,000 copies/mL and the CD4 cell
count was 726/mm3 (25%). Four months
prior outside records indicate his viral load
was 1,200 copies/mL.  
His current medications included
lopinavir/ritonavir, saquinavir, lamivudine,
gemfibrozil, fish oil and fluoxetine.  
His past antiretroviral history includes treat-
ment with each of the following:  zidovudine,
zalcitabine, didianosine, lamivudine, teno-
fovir, stavudine, abacavir, efavirenz, indinavir
and amprenavir.
A genotype was obtained on his current med-
ication and revealed the following mutations:
NRTI: 67N, 184V, (other mutations detected:
K219S)
NNRTI: None
PI mutations: 10I, 24I, 33F, 46L, 54V, 63P,
71V, 82A, 84V
Prior genotypes outside of prison reveal:
NRTI: 41L, 67N, 210W, 215Y, 184V
NNRTI: 103N, 181C 
PI: 10I, 24I, 33F, 46L, 54V, 71V, 82A, 84V 
Question: Taking into consideration the
genotype results, medication history and past
issues with adherence, what would be your
next antiretroviral regimen?  
Discussion: This patient has an extensive
past antiretroviral experience.  In addition, he
has had mental health and substance abuse
problems that have negatively impacted his
ability to adhere to his HIV therapies.  Since
his incarceration he has been seen by men-
tal health and is responding well to his anti-
depressant. After a 40-minute discussion
regarding his commitment to HIV therapy
during which he pledged to be adherent to
HIV and mental health care it was decided to
craft a new regimen of darunavir boosted with
ritonavir, and fixed dose emtricitabine/teno-
fovir and zidovudine were selected.  
Darunavir was selected despite the presence
of a few mutations associated with reduced
susceptibility to this protease inhibitor includ-
ing the 33F and 84V mutations.  Data from
the darunavir package insert suggest that as
many as 40% of treatment experienced
patients with two major mutations associated
with reduced darunavir susceptibility can
achieve reductions in viral load below 50
copies/mL at 24 weeks.  The patient harbors
virus that is resistant to all the non-nucleoside
reverse transcriptase inhibitors (NNRTI) and
even though these mutations are not evident
on his latest genotype resistance test, they
persist and will reemerge if NNRTIs are used.
Therefore, no currently approved NNRTIs
will work against his virus.  He also has
developed a number of damaging mutations
conferring resistance to drugs in the nucleo-
side reverse transcriptase inhibitor (NRTI)
class.  It is possible that his virus does retain
some susceptibility to tenofovir, so this drug
is being added to his regimen. In addition,
there are some data to suggest that mainte-
nance of the 184V mutation associated with
lamivudine and emtricitabine resistance
leads to reduced pathogenicity of HIV and
that continuation of these drugs may inhibit
the 'fitness' of the virus. Lastly, other data
indicate that HIV has difficulty maintaining
resistance mutations to both zidovudine and
tenofovir.  The use of zidovudine in this case
is somewhat novel and does not provide an
antiretroviral effect - as the genotype reveals
that the detected virus is resistant to this
NRTI - rather, it is an attempt to protect
against tenofovir resistance. 
The clinician and patient also discussed the
addition of enfuvirtide, an injected fusion
inhibitor. This agent would be expected to
provide additional antiretroviral activity and
work well with his new combination of med-
ications.  However, the patient was opposed
to twice-daily injections at this point and pre-
ferred to reserve this drug in case of subopti-
mal response to his new regimen or for a
subsequent regimen. 
Prior to receipt of his medications, the patient
was counseled regarding potential toxicities
of the drugs. He was encouraged to give the
medications a chance and told that his body
would most likely adjust should he have early
problems such as gastrointestinal discomfort.
After approximately 3 weeks, the patient
underwent laboratory testing. The viral had
decreased by 2 log10 to 936 copies/mL and
the patient was tolerating the medications.
He reported 100% adherence with the new
regimen and this was supported by nursing
records as his medications were adminis-
tered under direct observation. He reports
less fatique, despite addition of zidovudine.
Routine laboratory results were unremark-
able.  Six weeks after initiating his regimen
the viral load was less than 50 copies/mL and
the CD4 cell count was 810/mm3. A fasting
lipid panel revealed a triglyceride level of 165
mg/dL, LDL cholesterol of 102 mg/dL, and
cholesterol of 44 mg/dL on gemfibrozil and
fish oil capsules.  A return clinic visit at three
months after therapy initiation is scheduled to
document continued viral suppression, to
assess for adverse effects and adherence
and provide continued adherence counseling
and encouragement. 
Case 2: B.D. is a 45 year-old woman with
AIDS (CD4 nadir = 21/mm3), genital herpes
simplex and history of venous stasis disease.
She was diagnosed with HIV in 1994 and has
been treated with a variety of antiretrovirals
as listed below.  Early in her treatment she
suffered from intolerance to most of her HIV
medications and often was non-adherent.
However, over the years she has been able
to tolerate her HIV therapy and has become
adherent despite treatment with challenging
antiretroviral regimens. Her current medica-
tions (since about 12/03) are lopinavir/riton-
avir, lamivudine/zidovudine and tenofovir. 
Three months ago her CD4 cell count was
184/mm3 and her viral load was 38,000
copies/mL. A genoptype resistance test was
performed and revealed an extensive num-
ber of resistance mutations in each of the
three classes of antiretrovirals tested (see
101).  A repeat viral load is drawn and reveals
a viral load of 29,000 copies/mL but no sig-
nificant change in her CD4 cell count.
Her past antiretroviral history includes treat-
ment with each of the following agents:
Stavudine, didanosine, efavirenz, indinavir,
nelfinavir, saquinavir and amprenavir. 
Question: What would be her best next step
in treating her HIV infection?
Discussion: First, the patient should be
placed on appropriate prophylaxis for pneu-
mocystis jiroveci pneumonia (formerly, pneu-
mocystis carinii) then attention can turn to her
antiretroviral options.  Unfortunately, she now
has multi-drug resistant HIV and few of the
currently available antiretrovirals would be
predicted to suppress the replication of her
virus. The many resistance mutations her
HIV has developed are likely a consequence
of her inability to adhere to her medications,
especially when she was prescribed early
HIV agents that were more difficult to take
than current therapies. Further, her initial
therapy consisted of monotherapy with
zidovudine and then a series of dual NRTIs
with the subsequent addition of protease
inhibitors. These sequential rounds of subop-
timal therapy also contributed to the develop-
ment of drug resistance.  
Like the patient in Case 1, this patient has
mutations in the reverse transcriptase region
of her virus's genome that render all current
NNTRIs essentially useless. Her NRTI
options are almost equally as bleak, although
tenofovir may still retain some modicum of
activity. Likewise, she has few protease
inhibitor choices remaining.  Her genotype
detects mutations to darunavir and tipranavir;
however, unlike the case for current NNRTIs
resistance to these protease inhibitors, is
reduced with the accumulation of mutations
such that it may require development of four,
five or more major mutations to leave the
virus impervious to the antiretroviral activity
of these agents.  Therefore, with just two or
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9three such mutations, some activity of the
protease inhibitor agents can be expected.
Additionally, she is naïve to enfuvirtide and
she is willing to receive twice daily subcuta-
neous injections, if necessary.  
While we have the option of enfuvirtide we do
not have a critical mass of agents to add to
this drug to provide a regimen that could be
expected to reduce her viral load to unde-
tectable levels and keep it there.  Either
darunavir or tipranavir can be useful but the
resistance present may truncate their anti-
retroviral effect.  The addition of at least one
other new agent anticipated to be active
against this virus would increase confidence
in her 'salvage' regimen.  
Based on the data presented at CROI 2007,
we could expect the integrase inhibitor ralte-
gravir, to be effective against this patient's
virus (see main article). Participants in the
Benchmrk studies were, like our patient,
resistant to or experienced with drugs in all
three original classes of antiretrovirals. In
these studies those patients who received
raltegravir and either darunavir or enfuvirtide
(and were naïve to these two agents) had the
best outcomes.  Among those who took all
three agents, 98% achieved viral loads less
than 50 copies/mL at 16 weeks.  
TMC-125 would be another agent that may
provide some antiretroviral activity.  The
activity of TMC-125 is diminished as NNRTI
mutations accumulate, therefore, if she har-
bors additional mutations - acquired during
her treatment with efavirenz but not suffi-
ciently present now to be detected - this drug
may be less useful.  
Therefore, it is decided to maintain her cur-
rent therapy with the plan to start raltegravir,
darunavir/ritonavir, enfuvirtide and teno-
fovir/emtricitabine once the integrase
inhibitor becomes available, anticipated to be
within the next six months.  The risks of main-
taining the current regimen including the cul-
tivation of additional resistance mutations
versus discontinuing her regimen and experi-
encing an even greater rise in viremia and
attendant reduction in CD4 cell count are
explained to the patient.  She voices under-
standing of the considerations and opts to
continue on her present therapy until the ral-
tegravir becomes available and the new com-
bination can be started.
HIV RESISTANCE TESTING 101: GENOTYPE
Go to www.AAHIVM.org to learn about mem-
bership, continuing education and the new
partnership with IDCR
Summary of mutations
actually detected in
each drug class
List of mutations actually detected
that can affect response to specific
HIV medication
Predicted response to therapy 
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Updates in Correctional Health Care
Orlando, FL
May 5-8, 2007
Visit:www.ncchc.org/education
/index.html
The 34th Annual International
Conference on Global Health
May 29 - June 1, 2007
Washington, D.C.
Visit:www.globalhealth.org/2007_con-
ference/
The American Conference for the
Treatment of HIV (ACTHIV)
May 31 - June 3, 2007
Dallas, TX
Visit:www.acthiv.org
Medication Assisted Therapy
(MAT): Interventions for Drug Users
in Correctional Settings
American Correctional Health
Services Association (ACHSA) 2007
Multidisciplinary Professional
Development Conference
June 4, 2007
Reno, NV
Visit:http://www.achsa.org/display-
common.cfm?an=1&subarticlenbr=49
Dual Focus on Correctional Health:
Legal and Ethical Considerations
and Emerging Issues
American Correctional Health
Services Association (ACHSA) 2007
Multidisciplinary Professional
Development Conference
June 5-7, 2007
Reno, NV
Visit:http://www.achsa.org/display-
common.cfm?an=4
Correctional Mental Health Seminar
Las Vegas, NV
July 15-16, 2007
Visit:www.ncchc.org/education/MH200
7/lasvegas.html
IAS 2007: 4th IAS Conference on
HIV Pathogenesis, Treatment and
Prevention
Sydney, Australia
July 22-27, 2007
Visit:www.ias2007.org/start.aspx
National Conference on
Correctional Health Care
Nashville, TN
October 13-17
Visit:http://www.ncchc.org/education/n
ational2007.html
SAVE THE
DATES
10
Antibiotic Resistance Prompts Changes in
CDC's Treatment Guidelines for Gonorrhea
In the April 13th issue of MMWR, the CDC released
an updated recommendation of the Sexually
Transmitted Diseases Treatment Guidelines, 2006,
which no longer recommends treating gonorrhea
with fluoroquinolones antibiotics such as Cipro,
Floxin, and Levaquin. Instead of fluoroquinolones,
the CDC recommends the cephalosporin class of
antibiotics. The CDC has recommended fluoro-
quinolones as a gonorrhea treatment option since
1993. At first the class of drugs was extremely effec-
tive, but fluoroquinolone-resistant gonorrhea has
increased in recent years -- first in Hawaii, then
California, and then nationwide among men who
have sex with men. As a result, the CDC recom-
mended in 2000 and 2002 that fluoroquinolones not
be used to treat gonorrhea infections acquired only
in Hawaii and California. In 2004, they recommend-
ed that fluoroquinolones no longer be used to treat
gonorrhea in men who have sex with men across
the U.S. The CDC now recommends the use of
cephalosporins for treatment of all gonorrhea
cases. The CDC based its recommendations on
preliminary 2006 data showing that fluoroquinolone-
resistant gonorrhea is present nationwide and is
continuing to rise among heterosexual men and
among men who have sex with men. For more infor-
mation on the updated treatment recommendations
including drug regimens  visit:
http://www.cdc.gov/STD/treatment/2006/updated-
regimens.htm
CDC. Update to CDC's Sexually Transmitted
Diseases Treatment Guidelines, 2006:
Fluoroquinolones No Longer Recommended for
Treatment of Gonococcal Infections. Morb Mortal
Wkly Rep. 2007;56(14):332-36. Available at:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5
614a3.htm?s_cid=mm5614a3_e
Limited Spending: An Analysis of Correctional
Expenditures on Antiretrovirals for HIV-Infected
Prisoners
A substantial proportion of persons with HIV infec-
tion are incarcerated.  As such, jails and prisons are
important venues for the provision of HIV therapy.
In an effort to determine whether HIV therapy is
being adequately provided to inmates, researchers
from Brown Medical School performed an analysis
comparing national correctional system antiretrovi-
ral expenditures to the projected cost of such treat-
ment based on the number of inmates who are HIV-
infected.  Utilizing known HIV prevalence estimates
from the U.S. Bureau of Justice Statistics (BJS),
average HIV treatment costs, and national data on
pharmaceutical sales to correctional institutions, the
authors were able present real correctional expen-
ditures as a percentage of estimated total expendi-
tures to determine the unmet need within the incar-
cerated population.  
The results, published in Public Health Reports,
indicate that there is a substantial unmet need for
antiretrovirals in correctional health care, as total
antiretroviral sales represented only 29% of the
funds estimated to be required to treat all inmates
eligible for such treatment.  By end of 2003, there
were just over 23,600 state and federal prisoners
with known HIV infection - 1.9% of the incarcerated
population.  Based on Centers for Disease Control
and Prevention (CDC) data on antiretroviral therapy
usage among HIV-infected patients, 86% of inmates
should be receiving such therapy.  Multiplying the
number of inmates expected to be on antiretrovirals
with the estimated cost of HIV therapy, the authors
arrived at a total anticipated correctional antiretrovi-
ral expenditure of over $454 million.  However, pris-
ons only spent $52.5 million on antiretroviral med-
ications.  
In assessing the many limitations of the study, the
investigators note their reliance on BJS HIV preva-
lence data, which is drawn from only 19 prisons that
routinely test for inmates for HIV entry upon entry
into the facility and reports only those inmates with
known HIV infection.  Additionally, differing proto-
cols regarding initiation of HIV therapy and the use
drugs other than antiretrovirals may have con-
tributed to inaccuracy in the estimate of HIV-positive
individuals eligible for HIV therapy.  Despite the
many barriers to care, the authors underscore the
need for treatment of HIV-infected prisoners,
emphasizing the reduced costs associated with
HIV-related complications and linkage to HIV care in
the community.
Limited Spending: An Analysis of Correctional
Expenditures on Antiretrovirals for HIV-Infected
Prisoners.  Zaller, N. et al.  Public Health Reports.
2007 Jan-Feb; 122(1):49-54.
Substance Use and Sexual Behavior During
Incarceration Among 18- to 29-Year-Old Men:
Prevalence and Correlates
In this study, a supplement to a larger multi-site
intervention trial, investigators conducted an audio-
computer assisted self-interviewing (ACASI) survey
of 197 men with a history of incarceration, ages 18-
29 years, in order to assess substance abuse and
sexual behavior during incarceration.  The findings
support previous studies, revealing that 50% and
17% of participants, respectively, engaged in sub-
stance use or had consensual sex while incarcerat-
ed.  These behaviors were correlated and both were
associated with the following: being older, having
spent more years incarcerated, being sexually
abused, and involvement in gangs and violence
while incarcerated.  
Significantly, multiple regression analysis demon-
strated that behavior practices during incarceration
may reflect behavior practices in the community.
This relationship is manifested in the observation
that men were more likely to have had sex during
incarceration if they reported having a male partner
in the community.  Likewise, men were more likely
to use illegal substances during incarceration if they
reported hard drug use prior to incarceration.
Limitations of the study include a reliance on self-
reported behavior from a small convenience sample
of men and recall bias.  Nonetheless, the authors
assert that these findings emphasize the need for
future longitudinal research to explore the extent to
which men's experiences pre-to-post incarceration
are directly linked, not only to examine the ways
that pre-incarceration experience influences behav-
ior during incarceration, but also to study the ways
that incarceration experiences affect behavior in the
community following release from a correctional
facility.  Such research, the authors suggest, might
inform the development of novel or improved risk
reduction interventions.
Substance Use and Sexual Behavior During
Incarceration Among 18- to 29-Year-Old Men:
Prevalence and Correlates.  Seal, DW et al.  AIDS
Behavior.  2007 March 8
Compiled by Ross Boyce MS1 And Elizabeth
Closson
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SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for continuing
Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and IDCR.  MEC is accredited by the ACCME to
provide continuing medical education for physicians. 
Medical Education Collaborative designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.  Physicians should
only claim credit commensurate with the extent of their participation in the activity.  Statements of credit will be mailed within 6 to 8 weeks following
the program. 
11
1. True or False? The clinical use of Maraviroc (MVC) with treatment-
naïve patients appears to require pretreatment screening with a tro
pism assay because the drug will not be effective in those infected 
with a x4 or dual tropic virus. 
TRUE or FALSE?
2. According to the AIDS Clinical Trials Group (ACTG) study A5073, 
the unexpected finding of increased risk of virologic failure among 
those with higher viral loads assigned to once a day _________is 
concerning and requires further study. 
A. Lamivudine (3TC)
B. Lopinavir/ritonavir
C. Tenofovir
D. Atazanavir/ritonavir
3. The following is commonly prescribed with ritonavir boosted 
atazanavir even though this nucleotide analogue reduces 
atazanavir levels. 
A. Tenofovir
B. Efavirenz
C. Raltegravir
D. None of the above
4. In a study from Johns Hopkins on the eligibility of HIV/HCV co-
infected and HCV mono-infected injection drug users (IDUs) for 
HCV therapy, HIV co-infected patients were less likely to be eligible
for HCV therapy. 
TRUE or FALSE?
In order to receive credit, participants must score at least a 70% on the post test and submit it along with the credit 
application and evaluation form to the address/fax number indicated.  Statements of credit will be mailed within 6-8 weeks
following the program.
Please print clearly as illegible applications will result in a delay.
Name: _________________________________________________  Profession: __________________________________
License #: ___________________________________  State of License: __________________________________________
Address: ____________________________________________________________________________________________
City: ________________________ State: ________ Zip: ________________________ Telephone: ___________________
Please check which credit you are requesting  ___ ACCME   or    ___ Non Physicians
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
I certify that I participated in IDCR monograph - April 2007 Issue     
Please fill in the number of actual hours that you attended this activity.
Date of participation: ______________________  
Number of Hours (max. 1.25): ___________________
Signature: _________________________________________________
Please Submit Completed Application to:
Medical Education Collaborative
651 Corporate Circle, Suite 104, Golden CO 80401
Phone: 303-420-3252 FAX: 303-420-3259
For questions regarding the accreditation of this activity, please call
303-420-3252
Instructions:
• Applications for credit will be accepted until 
April 30, 2008.
• Late applications will not be accepted.
• Please anticipate 6-8 weeks to recieve your certificate.
Objectives:
The learner will become familiar with the new research and clinical trials presented at CROI pertaining to Maraviroc, Reltegravir, and current anti-
retrovirals. 
The learner will become familiar with the clinical trials and research of HIV/HCV infected patients presented at CROI. 
The learner will be able to analyze a genotype chart for HIV resistance testing. 
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COURSE EVALUATION
I. Please evaluate this educational activity by checking the appropriate box:
Activity Evaluation
Faculty
Content
How well did this activity avoid com-
mercial bias and present content that
was fair and balanced?
What is the likelihood you will
change the way you practice based
on what you learned in this activity?
Overall, how would you rate 
this activity?
Excellent Very Good Good Fair Poor
II. Course Objectives 
Were the following overall course objectives met?  At the conclusion of this presentation, are you able to:
• The learner will become familiar with the new research and clinical trials presented at CROI pertaining YES NO SOMEWHAT
to Maraviroc, Reltegravir, and current antiretrovirals.  
•  The learner will become familiar with the clinical trials and research of HIV/HCV infected patients presented        YES NO SOMEWHAT
at CROI. 
•  The learner will be able to analyze a genotype chart for HIV resistance testing. YES NO SOMEWHAT
III. Additional Questions
a. Suggested topics and/or speakers you would like for future activities.
b.  Additional Comments 
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